MMJ International Holdings Following FDA Guidance in Cannabis Drug Development Process

MMJ International Holdings Following FDA Guidance in Cannabis Drug Development Process

Publication date: May 11, 2019

ST. PETERSBURG, FL / ACCESSWIRE / May 10, 2019 / MMJ International Holdings, the premier medical cannabis research company, recently announced that the FDA has made an award for ”Orphan Drug Designation” for its THC and CBD proprietary drug formulation which will be used for the treatment of Huntington’s Disease.

This MMJ Orphan Drug award by the FDA means that MMJ has demonstrated its promise for the diagnosis and/or treatment of rare diseases or conditions.

Orphan designation qualifies MMJ International Holdings for various development incentives provided by the Orphan Drug Award, including tax credits for qualified clinical testing.

Concepts Keywords
Bear Regulatory manufacturing expertise
Boise Product sellers
Cannabinoid Product seizures
Cannabis Disease
CBD Treatment diseases
CEO Treatment rare diseases
Clinical Trials Health
DEA Articles
Drug Formulation Pharmaceuticals policy
FDA Life sciences
Huntington Orphan drug
Intellectual Property MMJ
Interstate Commerce
Marijuana
Orphan Drug
Protocol
Seizures
ST
THC

Semantics

Type Source Name
gene UNIPROT FHL5
gene UNIPROT NR4A2
disease MESH seizures
drug DRUGBANK Medical Cannabis
disease MESH Development
gene UNIPROT WAS
drug DRUGBANK Cannabidiol
disease MESH suffering
disease MESH diagnosis
gene UNIPROT POTEM
gene UNIPROT ACTG1
gene UNIPROT CEP55
gene UNIPROT SET
gene UNIPROT SERPINA3
gene UNIPROT ALG3
gene UNIPROT ACOT7
gene UNIPROT ACTG2
gene UNIPROT ACTBL2
gene UNIPROT CNTN2
disease MESH rare diseases

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *